Table 1.

PARP inhibitors in clinical trials

PARP inhibitorCompanyPARP1 IC50aClinical trialsbCombination therapiesb
Olaparib (AZD-2281)AstraZeneca5 nmol/LPhase I–IIIBevacizumab, carboplatin, cediranib, cisplatin, dacarbazine, doxorubicin, gefitinib, gemcitabine, irinotecan, mitomycin C, paclitaxel, radiation, temozolomide, topotecan
Veliparib (ABT-888)Abbott5.2 nmol/LPhase I–IIAbiraterone acetate, bendamustine, bevacizumab, bortezomib, capecitabine, carboplatin, cisplatin, cyclophosphamide, dexamethasone, dinacilib, docetaxel, doxorubicin, etoposide, floxuridine, fluorouracil, gemcitabine, irinotecan, leucovorin, mitomycin C, oxaliplatin, paclitaxel, prednisone, radiation, rituximab, temozolomide, topotecan, vinorelbine ditartrate
AZD-2461AstraZenecaNot publishedPhase INA
BMN-673BioMarin0.57 nmol/LPhase INA
CEP-9722Teva20 nmol/LPhase I–IICisplatin, gemcitabine, temozolomide
E-7016EisaiNot publishedPhase IITemozolomide
Niraparib (MK-4827)Tesaro3.8 nmol/LPhase ITemozolomide
Rucaparib (CO-338)Clovis1.7 nmol/LPhase I–IICarboplatin, cisplatin